ANI Pharmaceuticals, Inc. (ANIP) — Fair Value Analysis
Base-case fair value (P50): $95.06 · Current price: $82.87 · Verdict: Fairly Valued
The Verdict on ANIP
Based on our comprehensive Monte Carlo simulations, ANI PHARMACEUTICALS INC (ANIP) is currently deemed Fairly Valued. While the current market price of $82.87 sits below our median fair value (P50) of $95.06, the implied +14.7% falls within a range that suggests the stock is appropriately priced at this time. Our analysis indicates that ANIP's operational and financial health is robust, contributing to its strong quality tier rating within the Healthcare sector. This strong foundational quality supports its current valuation, suggesting a balance between its inherent value and market perception despite the calculated upside.
How ANIP stacks up against Healthcare
ANIP distinguishes itself within the competitive Healthcare sector with a strong quality tier rating, reflecting its sound operational and financial health. This tier signifies a company that exhibits resilience and fundamental strength compared to its industry peers. While the sector as a whole presents diverse investment opportunities and risks, ANIP’s strong quality tier provides a stable backdrop for its current market price of $82.87. The P50 fair value of $95.06 further anchors this view, indicating that the market is generally recognizing the underlying value inherent in a Healthcare company of this caliber, with a moderate +14.7% remaining.
What this means for investors
Investors considering ANIP should note its "Fairly Valued" status and strong quality tier. The Monte Carlo simulations, which consider thousands of forward scenarios, position ANIP's $82.87 as reasonable relative to its $95.06 fair value, despite the +14.7%. While there is an identified upside, it suggests a balanced risk-reward profile rather than a significant undervaluation. Investors seeking substantial discount opportunities might look elsewhere, but ANIP offers a fundamentally sound proposition within the Healthcare sector. Full details, including the bear case (P10) and bull case (P90) distribution for ANIP, are available. Sign up for a free FairCurve account to see ANIP's complete bear and bull distribution and track its fair value as new fundamentals are released.
Frequently Asked Questions
Is ANIP overvalued or undervalued right now?
Based on Monte Carlo simulations, ANI PHARMACEUTICALS INC (ANIP) is currently considered Fairly Valued. Its median fair value (P50) is $95.06 compared to its current price of $82.87.
What is the bear case and bull case for ANIP?
The full Monte Carlo distribution for ANIP, including specific bear (P10) and bull (P90) target prices, along with the probability of upside, is available with a free FairCurve account. We do not provide specific dollar values for these scenarios here.
How does FairCurve calculate ANIP's fair value?
FairCurve calculates ANIP's fair value using sophisticated Monte Carlo simulations, running thousands of forward scenarios to determine a probability-weighted valuation. This robust methodology generates our median fair value (P50) of $95.06.
How can I track ANIP's fair value as it changes?
You can add ANIP to a free FairCurve watchlist to receive daily updates on its fair value and get instant re-valuations whenever new earnings or significant fundamental data are released.